• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

四、十六和六十四个 PSMA 靶向配体修饰的三嗪树突聚合物的肿瘤摄取:被动与主动肿瘤靶向。

Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting.

机构信息

Department of Chemistry, Texas Christian University, Fort Worth, TX 76129, USA.

Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

出版信息

Biomolecules. 2019 Aug 28;9(9):421. doi: 10.3390/biom9090421.

DOI:10.3390/biom9090421
PMID:31466360
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6770530/
Abstract

Various glutamate urea ligands have displayed high affinities to prostate specific membrane antigen (PSMA), which is highly overexpressed in prostate and other cancer sites. The multivalent versions of small PSMA-targeted molecules are known to be even more efficiently bound to the receptor. Here, we employ a well-known urea-based ligand, 2-[3-(1,3-dicarboxypropyl)-ureido] pentanedioic acid (DUPA) and triazine dendrimers in order to study the effect of molecular size on multivalent targeting in prostate cancer. The synthetic route starts with the preparation of a dichlorotriazine bearing DUPA in 67% overall yield over five steps. This dichlorotriazine reacts with G1, G3, and G5 triazine dendrimers bearing a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) group for Cu-labeling at the core to afford poly(monochlorotriazine) intermediates. Addition of 4-aminomethylpiperidine (4-AMP) and the following deprotection produce the target compounds, G1-(DUPA), G3-(DUPA), and G5-(DUPA). These targets include 4/16/64 DUPA groups on the surface and a DOTA group at the core, respectively. In vitro cell assay using PC3-PIP (PSMA positive) and PC3-FLU (PSMA negative) cells reveals that G1-(DUPA) has the highest PC3-PIP to PC3-FLU uptake ratio (10-fold) through the PSMA-mediated specific uptake. While G5-(DUPA) displayed approximately 12 times higher binding affinity (IC 23.6 nM) to PC3-PIP cells than G1-(DUPA) (IC 282.3 nM) as evaluated in a competitive binding assay, the G5 dendrimer also showed high non-specific binding to PC3-FLU cells. In vivo uptake of the Cu-labeled dendrimers was also evaluated in severe combined inmmunodeficient (SCID) mice bearing PC3-PIP and PC3-FLU xenografts on each shoulder, respectively. Interestingly, quantitative imaging analysis of positron emission tomograph (PET) displayed the lowest tumor uptake in PC3-PIP cells for the midsize dendrimer G3-(DUPA) (19.4 kDa) (0.66 ± 0.15%ID/g at 1 h. p.i., 0.64 ± 0.11%ID/g at 4 h. p.i., and 0.67 ± 0.08%ID/g at 24 h. p.i.). Through the specific binding of G1-(DUPA) to PSMA, the smallest dendrimer (5.1 kDa) demonstrated the highest PC3-PIP to muscle and PC3-PIP to PC3-FLU uptake ratios (17.7 ± 5.5 and 6.7 ± 3.0 at 4 h p.i., respectively). In addition, the enhanced permeability and retention (EPR) effect appeared to be an overwhelming factor for tumor uptake of the largest dendrimer G5-(DUPA) as the uptake was at a similar level irrelevant to the PSMA expression.

摘要

各种谷氨酸尿素配体对前列腺特异性膜抗原(PSMA)表现出高亲和力,PSMA 在前列腺和其他癌灶中高度过表达。已知小 PSMA 靶向分子的多价版本与受体的结合效率更高。在这里,我们使用一种众所周知的基于尿素的配体 2-[3-(1,3-二羧基丙基)-脲基]戊二酸(DUPA)和三嗪树枝状大分子,研究分子大小对前列腺癌多价靶向的影响。合成路线从制备在五个步骤中总收率为 67%的带有 DUPA 的二氯三嗪开始。这种二氯三嗪与带有 1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)基团的 G1、G3 和 G5 三嗪树枝状大分子反应,在核心进行 Cu 标记,得到多(单氯三嗪)中间体。加入 4-氨基甲基哌啶(4-AMP)并随后脱保护,得到目标化合物 G1-(DUPA)、G3-(DUPA)和 G5-(DUPA)。这些靶标分别在表面具有 4/16/64 个 DUPA 基团和核心处的 DOTA 基团。使用 PC3-PIP(PSMA 阳性)和 PC3-FLU(PSMA 阴性)细胞进行的体外细胞测定表明,通过 PSMA 介导的特异性摄取,G1-(DUPA)具有最高的 PC3-PIP 与 PC3-FLU 摄取比(10 倍)。虽然 G5-(DUPA)在竞争性结合测定中对 PC3-PIP 细胞的结合亲和力(IC 23.6 nM)比 G1-(DUPA)(IC 282.3 nM)高约 12 倍,但 G5 树枝状大分子对 PC3-FLU 细胞也表现出高非特异性结合。还在分别在每个肩部携带 PC3-PIP 和 PC3-FLU 异种移植物的严重联合免疫缺陷(SCID)小鼠中评估了 Cu 标记树枝状大分子的体内摄取。有趣的是,正电子发射断层扫描(PET)的定量成像分析显示,对于中等大小的树枝状大分子 G3-(DUPA)(19.4 kDa),在 PC3-PIP 细胞中的肿瘤摄取最低(0.66±0.15%ID/g,1 h. p.i.,0.64±0.11%ID/g,4 h. p.i.,0.67±0.08%ID/g,24 h. p.i.)。通过 G1-(DUPA)与 PSMA 的特异性结合,最小的树枝状大分子(5.1 kDa)表现出最高的 PC3-PIP 与肌肉和 PC3-PIP 与 PC3-FLU 摄取比(4 h p.i.,分别为 17.7±5.5 和 6.7±3.0)。此外,增强的渗透性和保留(EPR)效应似乎是最大树枝状大分子 G5-(DUPA)肿瘤摄取的压倒性因素,因为摄取与 PSMA 表达无关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ef2/6770530/bd71508e1a7a/biomolecules-09-00421-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ef2/6770530/99b6fb5661f0/biomolecules-09-00421-ch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ef2/6770530/df5f9c3f7b87/biomolecules-09-00421-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ef2/6770530/c8598c343080/biomolecules-09-00421-sch002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ef2/6770530/341320f6b7a6/biomolecules-09-00421-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ef2/6770530/d666622ad855/biomolecules-09-00421-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ef2/6770530/aacb8b6ffc69/biomolecules-09-00421-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ef2/6770530/096832d8fc8f/biomolecules-09-00421-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ef2/6770530/bd71508e1a7a/biomolecules-09-00421-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ef2/6770530/99b6fb5661f0/biomolecules-09-00421-ch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ef2/6770530/df5f9c3f7b87/biomolecules-09-00421-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ef2/6770530/c8598c343080/biomolecules-09-00421-sch002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ef2/6770530/341320f6b7a6/biomolecules-09-00421-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ef2/6770530/d666622ad855/biomolecules-09-00421-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ef2/6770530/aacb8b6ffc69/biomolecules-09-00421-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ef2/6770530/096832d8fc8f/biomolecules-09-00421-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ef2/6770530/bd71508e1a7a/biomolecules-09-00421-g005.jpg

相似文献

1
Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting.四、十六和六十四个 PSMA 靶向配体修饰的三嗪树突聚合物的肿瘤摄取:被动与主动肿瘤靶向。
Biomolecules. 2019 Aug 28;9(9):421. doi: 10.3390/biom9090421.
2
Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.具有对前列腺癌的两种不同生物标志物(胃泌素释放肽受体/前列腺特异性膜抗原)亲和力的新型二价靶向载体——铜-64放射性标记的[DUPA-6-氨基己酸-(NODAGA)-5-氨基戊酸-蛙皮素(7-14)NH2]的合成与生物学评价
Nucl Med Biol. 2014 Apr;41(4):355-63. doi: 10.1016/j.nucmedbio.2014.01.001. Epub 2014 Jan 10.
3
Evaluation of PSMA-Targeted PAMAM Dendrimer Nanoparticles in a Murine Model of Prostate Cancer.PSMA 靶向 PAMAM 树枝状纳米粒子在前列腺癌小鼠模型中的评价。
Mol Pharm. 2019 Jun 3;16(6):2590-2604. doi: 10.1021/acs.molpharmaceut.9b00181. Epub 2019 May 6.
4
(2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy.用于PSMA靶向α粒子放射性药物治疗的(2S)-2-(3-(1-羧基-5-(4-²¹¹At-astatobenzamido)戊基)脲基)戊二酸
J Nucl Med. 2016 Oct;57(10):1569-1575. doi: 10.2967/jnumed.116.174300. Epub 2016 May 26.
5
Multimodal, PSMA-Targeted, PAMAM Dendrimer-Drug Conjugates for Treatment of Prostate Cancer: Preclinical Evaluation.多模态、PSMA 靶向、PAMAM 树枝状大分子-药物偶联物治疗前列腺癌的临床前评价。
Int J Nanomedicine. 2024 May 30;19:4995-5010. doi: 10.2147/IJN.S454128. eCollection 2024.
6
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.2-(3-{1-羧基-5-[(6-[18F]氟吡啶-3-羰基)-氨基]-戊基}-脲基)-戊二酸,[18F]DCFPyL,一种用于前列腺癌的 PSMA 基 PET 成像剂。
Clin Cancer Res. 2011 Dec 15;17(24):7645-53. doi: 10.1158/1078-0432.CCR-11-1357. Epub 2011 Oct 31.
7
Prostate-Specific Membrane Antigen Targeted Deep Tumor Penetration of Polymer Nanocarriers.前列腺特异性膜抗原靶向聚合物纳米载体的深部肿瘤穿透。
ACS Appl Mater Interfaces. 2022 Nov 16;14(45):50569-50582. doi: 10.1021/acsami.2c15095. Epub 2022 Nov 1.
8
Prostate-Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer.用于前列腺癌成像和治疗的前列腺特异性膜抗原靶向 StarPEG 纳米载体。
Adv Healthc Mater. 2024 Jul;13(19):e2304618. doi: 10.1002/adhm.202304618. Epub 2024 May 17.
9
[(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance.[18F]氟乙基三唑取代的PSMA抑制剂,具有快速的正常器官清除率。
Bioconjug Chem. 2016 Jul 20;27(7):1655-62. doi: 10.1021/acs.bioconjchem.6b00195. Epub 2016 Jun 24.
10
Development of F-Fluoroglycosylated PSMA-Ligands with Improved Renal Clearance Behavior.开发具有改善的肾脏清除行为的 F-氟代糖基 PSMA 配体。
Mol Pharm. 2020 Mar 2;17(3):933-943. doi: 10.1021/acs.molpharmaceut.9b01179. Epub 2020 Feb 17.

引用本文的文献

1
PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer.使用89Zr标记的星状聚乙二醇纳米载体的正电子发射断层扫描成像揭示了前列腺癌中增强的通透性和滞留的异质性。
Mol Cancer Ther. 2025 Jan 2;24(1):141-151. doi: 10.1158/1535-7163.MCT-24-0024.
2
PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?PSMA 靶向放射性核素治疗在现代核医学中的应用:过去、现在和未来?
Theranostics. 2024 May 13;14(8):3043-3079. doi: 10.7150/thno.92612. eCollection 2024.
3
Prostate-Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer.

本文引用的文献

1
Molar Activity of Ga-68 Labeled PSMA Inhibitor Conjugates Determines PET Imaging Results.镓-68 标记 PSMA 抑制剂缀合物的摩尔活性决定了 PET 成像结果。
Mol Pharm. 2018 Sep 4;15(9):4296-4302. doi: 10.1021/acs.molpharmaceut.8b00602. Epub 2018 Jul 27.
2
Synthesis of Symmetrical Tetrameric Conjugates of the Radiolanthanide Chelator DOTPI for Application in Endoradiotherapy by Means of Click Chemistry.通过点击化学合成用于内放射治疗的放射性镧系螯合剂DOTPI的对称四聚体缀合物。
Front Chem. 2018 Apr 10;6:107. doi: 10.3389/fchem.2018.00107. eCollection 2018.
3
Synthesis of novel multivalent fluorescent inhibitors with high affinity to prostate cancer and their biological evaluation.
用于前列腺癌成像和治疗的前列腺特异性膜抗原靶向 StarPEG 纳米载体。
Adv Healthc Mater. 2024 Jul;13(19):e2304618. doi: 10.1002/adhm.202304618. Epub 2024 May 17.
4
Targeted Doxorubicin-Loaded Dendronized Gold Nanoparticles.靶向载有阿霉素的树枝状金纳米颗粒。
Pharmaceutics. 2023 Aug 9;15(8):2103. doi: 10.3390/pharmaceutics15082103.
5
PSMA-Targeted Nanotheranostics for Imaging and Radiotherapy of Prostate Cancer.用于前列腺癌成像和放射治疗的PSMA靶向纳米诊疗剂
Pharmaceuticals (Basel). 2023 Feb 17;16(2):315. doi: 10.3390/ph16020315.
6
Dendrimer: An update on recent developments and future opportunities for the brain tumors diagnosis and treatment.树枝状大分子:脑肿瘤诊断与治疗的最新进展及未来机遇综述
Front Pharmacol. 2023 Mar 16;14:1159131. doi: 10.3389/fphar.2023.1159131. eCollection 2023.
7
A Theranostic Small-Molecule Prodrug Conjugate for Neuroendocrine Prostate Cancer.一种用于神经内分泌前列腺癌的诊疗小分子前药缀合物。
Pharmaceutics. 2023 Feb 1;15(2):481. doi: 10.3390/pharmaceutics15020481.
8
Prostate-Specific Membrane Antigen Targeted Deep Tumor Penetration of Polymer Nanocarriers.前列腺特异性膜抗原靶向聚合物纳米载体的深部肿瘤穿透。
ACS Appl Mater Interfaces. 2022 Nov 16;14(45):50569-50582. doi: 10.1021/acsami.2c15095. Epub 2022 Nov 1.
9
Two Decades of Triazine Dendrimers.二十年三嗪树状大分子。
Molecules. 2021 Aug 6;26(16):4774. doi: 10.3390/molecules26164774.
10
The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research.前列腺特异性膜抗原(PSMA)靶向放射性核素治疗的未来:近期临床前研究综述
Pharmaceutics. 2019 Oct 29;11(11):560. doi: 10.3390/pharmaceutics11110560.
新型多价荧光抑制剂的合成及其对前列腺癌的高亲和力和生物学评价。
Bioorg Med Chem Lett. 2018 Feb 15;28(4):572-576. doi: 10.1016/j.bmcl.2018.01.047. Epub 2018 Jan 31.
4
Cancer statistics, 2018.癌症统计数据,2018 年。
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
5
Be Active or Not: the Relative Contribution of Active and Passive Tumor Targeting of Nanomaterials.主动与否:纳米材料主动与被动肿瘤靶向的相对贡献
Nanotheranostics. 2017 Jul 11;1(4):346-357. doi: 10.7150/ntno.19380. eCollection 2017.
6
Ligand-Targeted Drug Delivery.配体靶向药物递送。
Chem Rev. 2017 Oct 11;117(19):12133-12164. doi: 10.1021/acs.chemrev.7b00013. Epub 2017 Sep 12.
7
Dual-Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in Radiotherapy.基于正电子发射断层扫描的放疗法用双核素放射性药物
Chemistry. 2018 Jan 12;24(3):547-550. doi: 10.1002/chem.201702335. Epub 2017 Sep 14.
8
Dendritic poly-chelator frameworks for multimeric bioconjugation.用于多聚体生物共轭的树枝状多螯合剂框架
Chem Commun (Camb). 2017 Feb 23;53(17):2586-2589. doi: 10.1039/c6cc10169k.
9
Design of a Small-Molecule Drug Conjugate for Prostate Cancer Targeted Theranostics.用于前列腺癌靶向诊疗的小分子药物偶联物设计
Bioconjug Chem. 2016 Jul 20;27(7):1681-9. doi: 10.1021/acs.bioconjchem.6b00222. Epub 2016 Jun 15.
10
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.使用¹⁷⁷Lu标记的PSMA-617对转移性去势抵抗性前列腺癌进行PSMA靶向放射性核素治疗。
J Nucl Med. 2016 Aug;57(8):1170-6. doi: 10.2967/jnumed.115.171397. Epub 2016 Mar 16.